ETON
VENTE TOTALE: 150 000 titres (~8 971 265,44 $ US)
- Insiders
- MAIER PAUL V, BRYNJELSEN SEAN
- Total bought
- —
- Total sold
- $8,971,265
- Last activity
- 2026-08-28
- Last synced
-
2026-09-03 09:53:14
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Neutral signal Scored 2026-08-26
ETON presents a genuine earnings catalyst with a 99% product sales growth beat and raised guidance above $145M, supported by a new drug licensing deal, but the event-driven upside is meaningfully capped by a significant…
The first sentence of the analysis written for ETON on 2026-08-26 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 53.5% | 60.0% | 66.6% | 67.4% | 88.0% | |
| Ebit Margin | 0.3% | -4.6% | -2.2% | -42.4% | -9.0% | |
| Ebitda Margin | 5.3% | -1.7% | 0.7% | -34.1% | -6.8% | |
| Operating Profit Margin | 0.1% | -6.7% | -3.8% | -38.9% | -6.8% | |
| Pretax Profit Margin | -5.7% | -9.8% | -2.2% | -42.4% | -9.0% | |
| Continuous Operations Profit Margin | -5.8% | -9.8% | -3.0% | -42.4% | -9.0% | |
| Net Profit Margin | -5.8% | -9.8% | -3.0% | -42.4% | -9.0% | |
| Bottom Line Profit Margin | -5.8% | -9.8% | -3.0% | -42.4% | -9.0% | |
| Current Ratio | 1.574 | 2.056 | 1.653 | 3.096 | 5.179 | |
| Quick Ratio | 1.173 | 1.293 | 1.596 | 3.010 | 5.058 | |
| Solvency Ratio | -0.008 | -0.052 | -0.002 | -0.606 | -0.152 | |
| Cash Ratio | 0.674 | 0.749 | 1.317 | 2.524 | 3.161 | |
| Price To Earnings Ratio | -99.471 | -88.800 | -120.000 | -7.833 | -55.284 | |
| Price To Earnings Growth Ratio | -7.460 | -0.286 | 1.335 | -0.022 | 0.587 | |
| Forward Price To Earnings Growth Ratio | -7.460 | -0.286 | 1.335 | -0.022 | 0.587 | |
| Price To Earnings Diluted Ratio | -99.471 | -88.800 | -120.000 | -7.833 | -55.284 | |
| Price To Earnings Diluted Growth Ratio | -7.460 | -0.286 | 1.335 | -0.022 | 0.587 | |
| Price To Book Ratio | 17.398 | 14.120 | 7.258 | 5.422 | 6.134 | |
| Price To Sales Ratio | 5.691 | 8.842 | 3.550 | 3.337 | 4.953 | |
| Price To Free Cash Flow Ratio | 44.649 | 365.770 | 18.597 | 34.880 | -13.551 | |
| Price To Operating Cash Flow Ratio | 43.236 | 355.956 | 16.482 | 14.709 | -22.906 | |
| Debt To Assets Ratio | 0.337 | 0.394 | 0.170 | 0.261 | 0.244 | |
| Debt To Equity Ratio | 1.186 | 1.228 | 0.349 | 0.499 | 0.380 | |
| Debt To Capital Ratio | 0.543 | 0.551 | 0.259 | 0.333 | 0.275 | |
| Long Term Debt To Capital Ratio | 0.454 | 0.550 | 0.000 | 0.292 | 0.230 | |
| Financial Leverage Ratio | 3.522 | 3.116 | 2.051 | 1.914 | 1.558 | |
| Working Capital Turnover Ratio | 3.704 | 2.463 | 2.621 | 1.304 | 1.093 | |
| Operating Cash Flow Ratio | 0.273 | 0.049 | 0.420 | 0.746 | -1.036 | |
| Operating Cash Flow Sales Ratio | 0.132 | 0.025 | 0.215 | 0.227 | -0.216 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.968 | 0.973 | 0.886 | 0.422 | 1.690 | |
| Debt Service Coverage Ratio | 0.311 | -0.323 | -0.005 | -3.645 | -0.607 | |
| Interest Coverage Ratio | 0.015 | -1.295 | -1.125 | -8.649 | -1.435 | |
| Short Term Operating Cash Flow Coverage Ratio | 1.197 | 12.750 | 1.267 | 4.667 | -3.329 | |
| Operating Cash Flow Coverage Ratio | 0.339 | 0.032 | 1.262 | 0.739 | -0.705 | |
| Capital Expenditure Coverage Ratio | 31.604 | 37.269 | 8.794 | 1.729 | -1.449 | |
| Dividend Paid And Capex Coverage Ratio | 31.604 | 37.269 | 8.794 | 1.729 | -1.449 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 107.825 | -547.914 | 454.430 | -8.435 | -67.265 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 53.5% | ▼-6.6% | ▼-13.6% |
| Ebit Margin | 0.3% | ▲4.9% | ▲11.9% |
| Ebitda Margin | 5.3% | ▲7.0% | ▲12.7% |
| Operating Profit Margin | 0.1% | ▲6.8% | ▲11.3% |
| Pretax Profit Margin | -5.7% | ▲4.1% | ▲8.1% |
| Continuous Operations Profit Margin | -5.8% | ▲4.0% | ▲8.2% |
| Net Profit Margin | -5.8% | ▲4.0% | ▲8.2% |
| Bottom Line Profit Margin | -5.8% | ▲4.0% | ▲8.2% |
| Current Ratio | 1.574 | ▼-0.483 | ▼-1.138 |
| Quick Ratio | 1.173 | ▼-0.119 | ▼-1.253 |
| Solvency Ratio | -0.008 | ▲0.043 | ▲0.156 |
| Cash Ratio | 0.674 | ▼-0.075 | ▼-1.011 |
| Price To Earnings Ratio | -99.471 | ▼-10.671 | ▼-25.193 |
| Price To Earnings Growth Ratio | -7.460 | ▼-7.175 | ▼-6.291 |
| Forward Price To Earnings Growth Ratio | -7.460 | ▼-7.175 | ▼-6.291 |
| Price To Earnings Diluted Ratio | -99.471 | ▼-10.671 | ▼-25.193 |
| Price To Earnings Diluted Growth Ratio | -7.460 | ▼-7.175 | ▼-6.291 |
| Price To Book Ratio | 17.398 | ▲3.278 | ▲7.331 |
| Price To Sales Ratio | 5.691 | ▼-3.150 | ▲0.417 |
| Price To Free Cash Flow Ratio | 44.649 | ▼-321.122 | ▼-45.420 |
| Price To Operating Cash Flow Ratio | 43.236 | ▼-312.720 | ▼-38.260 |
| Debt To Assets Ratio | 0.337 | ▼-0.057 | ▲0.056 |
| Debt To Equity Ratio | 1.186 | ▼-0.042 | ▲0.458 |
| Debt To Capital Ratio | 0.542 | ▼-0.009 | ▲0.150 |
| Long Term Debt To Capital Ratio | 0.454 | ▼-0.095 | ▲0.149 |
| Financial Leverage Ratio | 3.522 | ▲0.406 | ▲1.090 |
| Working Capital Turnover Ratio | 3.704 | ▲1.241 | ▲1.467 |
| Operating Cash Flow Ratio | 0.273 | ▲0.225 | ▲0.183 |
| Operating Cash Flow Sales Ratio | 0.132 | ▲0.107 | ▲0.055 |
| Free Cash Flow Operating Cash Flow Ratio | 0.968 | ▼-0.005 | ▼-0.020 |
| Debt Service Coverage Ratio | 0.311 | ▲0.634 | ▲1.165 |
| Interest Coverage Ratio | 0.015 | ▲1.310 | ▲2.513 |
| Short Term Operating Cash Flow Coverage Ratio | 1.197 | ▼-11.553 | ▼-2.113 |
| Operating Cash Flow Coverage Ratio | 0.339 | ▲0.307 | ▲0.006 |
| Capital Expenditure Coverage Ratio | 31.604 | ▼-5.666 | ▲16.014 |
| Dividend Paid And Capex Coverage Ratio | 31.604 | ▼-5.666 | ▲16.014 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 107.825 | ▲655.739 | ▲120.097 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $455.0M | $344.9M | $112.3M | $70.9M | $108.1M | |
| Enterprise value | $460.1M | $360.0M | $96.3M | $61.1M | $100.4M | |
| EV / Sales | 5.75x | 9.23x | 3.04x | 2.88x | 4.60x | |
| EV / Op. cash flow | 43.72x | 371.50x | 14.14x | 12.68x | -21.27x | |
| EV / Free cash flow | 45.15x | 381.74x | 15.95x | 30.07x | -12.59x | |
| EV / EBITDA | 107.83x | -547.91x | 454.43x | -8.44x | -67.27x | |
| Net debt / EBITDA | 1.19x | -22.92x | -75.41x | 1.35x | 5.17x | |
| Current ratio | 1.57x | 2.06x | 1.65x | 3.10x | 5.18x | |
| Income quality | -2.29x | -0.25x | -7.28x | -0.53x | 2.42x | |
| Graham net-net | -$1 | -$1 | $0 | $0 | $0 | |
| Tax burden | 100.9% | 100.4% | 135.8% | 100.0% | 100.0% | |
| Interest burden | -2043.9% | 211.2% | 100.0% | 100.0% | 100.0% | |
| Working capital | $22.1M | $21.1M | $10.6M | $13.5M | $19.0M | |
| Invested capital | $53.6M | $56.2M | $15.5M | $18.6M | $22.9M | |
| Return on assets | -5.0% | -5.0% | -2.9% | -36.0% | -7.1% | |
| Operating ROA | 0.1% | -4.8% | -4.2% | -31.5% | -5.6% | |
| Return on tangible assets | -7.5% | -9.3% | -3.5% | -44.5% | -8.2% | |
| Return on equity | -17.6% | -15.7% | -6.0% | -69.0% | -11.1% | |
| Return on invested capital | 0.1% | -4.6% | -5.7% | -42.1% | -6.1% | |
| Return on capital employed | 0.1% | -4.6% | -7.7% | -44.5% | -6.5% | |
| Earnings yield | -1.0% | -1.1% | -0.8% | -12.7% | -1.8% | |
| Free cash flow yield | 2.2% | 0.3% | 5.4% | 2.9% | -7.4% | |
| Capex / Op. cash flow | 3.2% | 2.7% | 11.4% | 57.8% | -69.0% | |
| Capex / Depreciation | 8.2% | 2.3% | 86.0% | 157.2% | 705.4% | |
| Capex / Sales | 0.4% | 0.1% | 2.4% | 13.1% | 14.9% | |
| SG&A / Sales | 44.8% | 58.3% | 59.8% | 87.4% | 66.3% | |
| R&D / Sales | 9.7% | 8.3% | 10.5% | 18.8% | 28.6% | |
| Stock comp / Sales | 6.9% | 8.1% | 9.9% | 19.8% | 15.5% | |
| Intangibles / Total assets | 33.5% | 45.8% | 14.9% | 19.0% | 13.2% | |
| Days sales outstanding | 54d | 50d | 39d | 32d | 91d | |
| Days payables outstanding | 108d | 97d | 64d | 93d | 247d | |
| Operating cycle | 205d | 407d | 71d | 61d | 168d | |
| Cash conversion cycle | 97d | 309d | 7d | -32d | -79d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+31.9%EV / Sales ▼-37.6%EV / EBITDA ▲+119.7%EV / Op. cash flow ▼-327.778Earnings yield ▲+0.001
Profitability
Return on equity ▼-0.019Return on assets +0.000Return on invested capital ▲+0.047Return on capital employed ▲+0.048Operating ROA ▲+0.049Income quality ▼-2.034Tax burden ▲+0.005
Efficiency
Days sales outstanding ▲+3.516Days payables outstanding ▲+10.169Operating cycle ▼-201.626Cash conversion cycle ▼-211.795Capex / Sales ▲+0.003R&D / Sales ▲+0.014
Balance-sheet strength
Current ratio ▼-0.483Net debt / EBITDA ▲+24.109Working capital ▲+1017000.000Invested capital ▼-2559000.000Intangibles / Total assets ▼-0.123
Change over 5 years
Valuation
Market cap ▲+320.8%EV / Sales ▲+25.1%EV / EBITDA ▲+260.3%EV / Op. cash flow ▲+64.991Earnings yield ▲+0.008
Profitability
Return on equity ▼-0.065Return on assets ▲+0.021Return on invested capital ▲+0.063Return on capital employed ▲+0.067Operating ROA ▲+0.056Income quality ▼-4.702Tax burden ▲+0.009
Efficiency
Days sales outstanding ▼-37.792Days payables outstanding ▼-139.193Operating cycle ▲+36.921Cash conversion cycle ▲+176.114Capex / Sales ▼-0.145R&D / Sales ▼-0.188
Balance-sheet strength
Current ratio ▼-3.605Net debt / EBITDA ▼-3.975Working capital ▲+3045000.000Invested capital ▲+30719000.000Intangibles / Total assets ▲+0.203
Employee count
Peer market caps
Congressional trades
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2022-10-11 | Thomas Suozzi | Purchase | $15,001 - $50,000 |
Recent news
- 2026-09-02 Connor Clark & Lunn Investment Management Ltd. Makes New $476,000 Investment in Eton Pharmaceuticals, Inc. $ETON Connor Clark and Lunn Investment Management Ltd. purchased a new stake in Eton Pharmaceuticals, Inc. (NASDAQ: ETON) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 13,150 shares of the company''s stock, valued at approximately $476,000. Other large investors have also
- 2026-08-31 BlackRock Inc. Invests $68.63 Million in Eton Pharmaceuticals, Inc. $ETON BlackRock Inc. bought a new position in Eton Pharmaceuticals, Inc. (NASDAQ: ETON) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 1,895,833 shares of the company''s stock, valued at approximately $68,629,000. BlackRock Inc. owned about 6.92% of Eton Pharmaceuticals at the
- 2026-08-30 Eton Pharmaceuticals, Inc. $ETON Stock Holdings Increased by Bank of America Corp DE Bank of America Corp DE boosted its holdings in shares of Eton Pharmaceuticals, Inc. (NASDAQ: ETON) by 37.8% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 144,367 shares of the company''s stock after purchasing an additional 39,571 shares
- 2026-08-28 Bank of Nova Scotia Acquires New Position in Eton Pharmaceuticals, Inc. $ETON Bank of Nova Scotia acquired a new stake in shares of Eton Pharmaceuticals, Inc. (NASDAQ: ETON) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 17,200 shares of the company''s stock, valued at approximately $623,000. Bank of Nova Scotia owned about
- 2026-08-27 Eton Pharmaceuticals to Participate at 2026 Wells Fargo Healthcare Conference DEER PARK, Ill., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company''s executive leadership team will host 1x1 meetings on September 9, 2026 at the 2026 Wells Fargo Healthcare Conference being held September 8-10, 2026 in Boston, MA.
- 2026-08-14 Why Eton Pharmaceuticals Is Top of the Class Today Eton Pharmaceuticals beat on both top and bottom lines last night. Management is licensing a new drug, and raising guidance through the end of 2026.
- 2026-08-14 Eton Pharmaceuticals: No Reason Pharma Can''t Deliver More Great Earnings Like These Eton Pharmaceuticals, Inc. delivered record Q2 2026 results, with product sales up 99% and full-year revenue guidance raised to over $145 million. ETON targets over $500 million in peak annual sales by leveraging organic growth, pipeline development, and strategic acquisitions in rare disease markets. Management expects adjusted EBITDA margins to exceed 35% in 2026, aiming for 50% by 2028, with gross margins rising from 70% to over 75%.
- 2026-08-14 Eton Pharmaceuticals, Inc. (ETON) Q2 2026 Earnings Call Transcript Eton Pharmaceuticals, Inc. (ETON) Q2 2026 Earnings Call Transcript
- 2026-08-13 Eton Pharmaceuticals Q2 Earnings Call Highlights Eton Pharmaceuticals NASDAQ: ETON reported second-quarter revenue nearly doubled from a year earlier, driven by the relaunch of HEMANGEOL and growth across its pediatric endocrinology and rare-disease portfolio. The company raised its full-year revenue and profitability outlook while outlining plans to advance newly acquired and internally developed products.
- 2026-08-13 Eton Pharmaceuticals, Inc. (ETON) Q2 Earnings and Revenues Beat Estimates Eton Pharmaceuticals, Inc. (ETON) came out with quarterly earnings of $0.35 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to a loss of $0.1 per share a year ago.